Daily Anesthesiology Research Analysis
Analyzed 105 papers and selected 3 impactful papers.
Summary
Three impactful studies span mechanistic analgesic discovery, obstetric anesthetic hemodynamics, and perioperative risk stratification. A cryo-EM–guided pipeline delivered a picomolar TRPM3 antagonist with robust analgesia in rodent pain models; a multicenter RCT showed maintaining systolic blood pressure ≥90% of baseline with noradrenaline during cesarean delivery reduced neonatal acidaemia and maternal hypotension; and an OSA hypoxic-burden metric independently predicted 30-day postoperative cardiovascular events.
Research Themes
- Structure-guided discovery of non-opioid analgesics (TRPM3 antagonism)
- Hemodynamic targets with vasopressors in obstetric anesthesia
- Perioperative risk stratification using sleep apnea hypoxic burden
Selected Articles
1. Cryo-EM structure enabling virtual screening for the discovery of highly potent TRPM3 antagonists with analgesic efficacy.
Using cryo-EM structures of human TRPM3, the authors identified a compact binding pocket that enabled virtual screening and lead optimization to a picomolar antagonist with favorable drug-like properties. The compound produced strong, dose-dependent analgesia in rodent neuropathic and migraine pain models, validating TRPM3 as a non-opioid analgesic target.
Impact: This study delivers a structure-guided, high-potency TRPM3 antagonist with in vivo analgesic efficacy, representing a major advance toward non-opioid pain therapeutics. It also establishes a generalizable discovery pipeline for TRP channels.
Clinical Implications: While preclinical, TRPM3 antagonism could yield non-opioid perioperative and chronic pain options with reduced respiratory depression and dependence risk. Translation will require first-in-human safety, selectivity, and efficacy trials.
Key Findings
- Cryo-EM resolved human TRPM3 structures and revealed a compact ligand-binding pocket.
- Virtual screening and structure-based optimization produced a picomolar TRPM3 antagonist with drug-like properties.
- The lead compound showed potent, dose-dependent analgesia across rodent neuropathic and migraine pain models.
- The work validates TRPM3 as a therapeutic target and outlines a structure-based pipeline for TRP channel drug discovery.
Methodological Strengths
- High-resolution cryo-EM structural elucidation enabling rational ligand design
- Integrated virtual screening with in vivo validation across multiple pain models
Limitations
- Preclinical evidence only; no human pharmacokinetic or safety data
- Selectivity, off-target effects within the TRP family, and long-term toxicity remain to be established
Future Directions: Advance to IND-enabling studies including selectivity profiling, GLP toxicology, pharmacokinetics, and early-phase clinical trials to assess safety and analgesic efficacy.
Current analgesics are limited by insufficient efficacy and adverse effects. TRPM3, a non-opioid target expressed in sensory neurons, represents a promising yet challenging therapeutic avenue due to a lack of potent, selective antagonists and unresolved structural pharmacology. We determined cryo-electron microscopy (cryo-EM) structures of human TRPM3, identifying a compact ligand-binding pocket that enabled large-scale virtual screening. Structure-based lead optimization yielded a picomolar antagonist with favorable drug-like properties. This compound exhibited potent, dose-dependent analgesia across multiple rodent models of neuropathic and migraine pain. Our work establishes a structure-based discovery pipeline for TRP channels, delivering a high-potency antagonist that validates TRPM3 as a therapeutic target and provides a framework for rational drug design against other ion channels.
2. Effect on neonatal outcomes of maintenance of maternal blood pressure targets with noradrenaline after spinal anaesthesia for caesarean delivery: a multicentre, randomised, controlled trial.
In 1183 women undergoing cesarean under spinal anesthesia, targeting systolic BP within 90% (vs 80%) of baseline using noradrenaline boluses did not change mean umbilical artery pH but reduced the incidence of umbilical artery pH <7.2. Maternal hypotension, severe hypotension, and nausea/vomiting were significantly less frequent in the 90% target group.
Impact: Provides high-quality randomized evidence to refine vasopressor-driven BP targets in obstetric anesthesia, balancing maternal hemodynamics and neonatal acid-base status.
Clinical Implications: For cesarean delivery under spinal anesthesia, maintaining systolic BP ≥90% of baseline with noradrenaline boluses may reduce neonatal acidaemia and maternal hypotension-related symptoms. Protocols should consider higher BP targets while monitoring for vasopressor overuse.
Key Findings
- Mean umbilical artery pH was similar between SBP-90% and SBP-80% targets (7.33 vs 7.33).
- Umbilical artery pH <7.2 was less frequent with the 90% target (0.5% vs 2.2%; p=0.020).
- Maternal hypotension (<80% baseline), severe hypotension (<60%), and nausea/vomiting were all significantly reduced with the 90% target.
- Achieving the 90% target required more noradrenaline boluses (median 2 vs 1).
Methodological Strengths
- Multicenter randomized controlled design with large sample size
- Clinically relevant maternal and neonatal endpoints and prespecified BP targets
Limitations
- Noradrenaline bolus regimen may limit generalizability to other vasopressors or infusion strategies
- Short-term neonatal outcomes emphasized; longer-term outcomes not reported
Future Directions: Compare continuous vs bolus vasopressor strategies and evaluate long-term neonatal neurodevelopment under different BP targets; assess applicability in emergency cesarean and high-risk populations.
INTRODUCTION: Hypotension after spinal anaesthesia for caesarean delivery can cause maternal and neonatal harm. However, excessive vasopressor therapy may also result in harm, and the optimal blood pressure target is unclear. We compared two different maternal blood pressure targets during caesarean delivery. METHODS: Women with term pregnancies undergoing caesarean delivery under spinal anaesthesia were assigned randomly to maintenance of systolic blood pressure within 90% (SBP-90% group) or 80% (SBP-80% group) of baseline readings, from intrathecal injection until delivery. The primary outcome was umbilical artery pH. Secondary outcomes included incidence of umbilical artery pH < 7.2 and maternal adverse events. RESULTS: Data from 1183 women were analysed (SBP-90% group, n = 590; SBP-80% group, n = 593). There was no difference in the mean (SD) umbilical artery pH between the SBP-90% and SBP-80% groups (7.33 (0.04) vs. 7.33 (0.05), p = 0.11). There were fewer incidences of umbilical artery pH < 7.2 in women allocated to the SBP-90% group compared with the SBP-80% group (3 (0.5%) vs. 13 (2.2%), p = 0.020). Patients allocated to the SBP-90% group had fewer episodes of maternal hypotension (< 80% of baseline systolic; 213 (36.1%) vs. 418 (70.5%), p < 0.001); severe hypotension (< 60% of baseline systolic; 23 (3.9%) vs. 46 (7.8%), p = 0.006); and nausea and vomiting (58 (9.8%) vs. 109 (18.4%), p < 0.001). Patients allocated to the SBP-90% group received more noradrenaline boluses (median (IQR [range]) 2 (1-3 [0-14]) vs. 1 (0-2 [0-14]), p < 0.001) when compared with the SBP-80% control group. DISCUSSION: During caesarean delivery under spinal anaesthesia, maintaining maternal systolic blood pressure > 90% of baseline, compared with > 80% of baseline, with boluses of noradrenaline reduces the incidence of neonatal acidaemia, maternal hypotension and nausea and vomiting.
3. Sleep Apnea-Specific Hypoxic Burden and Postoperative Outcomes of Major Noncardiothoracic Surgery.
In a multicenter cohort of 2286 OSA patients undergoing major noncardiothoracic surgery, higher sleep apnea–specific hypoxic burden at diagnosis was associated with increased odds of 30-day postoperative cardiovascular events and mortality. A risk score incorporating age, preoperative emergency admission, and SASHB (AUC 0.73) and a simplified oximetry-based SASHB yielded similar predictive performance.
Impact: Identifies a physiologically grounded OSA severity metric that stratifies short-term postoperative cardiovascular risk and can be derived from standard sleep study signals, enabling pragmatic perioperative risk assessment.
Clinical Implications: Incorporating SASHB into preoperative evaluation may improve identification of OSA patients at elevated 30-day cardiovascular risk, supporting targeted monitoring, hemodynamic vigilance, and optimization of sleep apnea management.
Key Findings
- Event rates rose from 1.6% (low SASHB) to 5.8% (high SASHB) for the 30-day composite outcome.
- Adjusted odds of the primary outcome increased with higher SASHB (aOR 1.76 and 2.79 for intermediate and high vs low).
- A risk score using age, emergency admission, and SASHB had an AUC of 0.73.
- A simplified SASHB derived from oximetry alone showed similar predictive performance.
Methodological Strengths
- Multicenter clinic-based cohort linked to administrative outcomes
- Use of a physiologically meaningful exposure (area under desaturation curve) with validation using simplified oximetry
Limitations
- Observational design with potential residual confounding and incomplete capture of perioperative management (e.g., CPAP adherence)
- OSA diagnosis-to-surgery interval was variable, and risk may change over time
Future Directions: Prospective interventional studies to test whether SASHB-guided perioperative pathways (e.g., monitoring, PAP optimization) reduce 30-day cardiovascular events.
IMPORTANCE: Obstructive sleep apnea (OSA) is a highly prevalent and heterogeneous condition that predisposes to postoperative complications. Adequate metrics of OSA severity to stratify postoperative risk in a clinical setting are needed. OBJECTIVE: To evaluate whether the sleep apnea-specific hypoxic burden (SASHB) is associated with postoperative cardiovascular (CV) complications and mortality among patients with OSA undergoing major noncardiothoracic surgery. DESIGN, SETTING, AND PARTICIPANTS: Multicenter clinic-based cohort linked with a health administrative database involving adult patients diagnosed with OSA between May 2007 and December 2018 who underwent major noncardiothoracic surgery between OSA diagnosis and December 2024. Data were analyzed from January to December 2025. EXPOSURE: SASHB defined as the area under the desaturation curve associated with sleep-related obstructive respiratory events. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of stroke, atrial fibrillation, heart failure, myocardial infarction, venous thromboembolism, and all-cause mortality within 30 days of surgery. The association of SASHB and other OSA severity metrics with the primary outcome was investigated using univariable and multivariable analyses. RESULTS: Among 2286 patients with OSA (median [IQR] age, 58 [49-66] years; 1472 [64.4%] men) who underwent major noncardiothoracic surgery a median (IQR) of 4.5 (1.9-7.5) years after OSA diagnosis, the primary outcome occurred in 80 patients (3.5%) within 30 days of surgery. The rate of events increased significantly from 1.6% (12 events) in patients with low SASHB (<32% min/h) to 5.8% (44 events) in those with high SASHB (≥80% min/h) at diagnosis. Compared with patients with low SASHB, patients with higher SASHB at diagnosis exhibited increased odds for the primary outcome (adjusted odds ratios, 1.76; 95% CI, 0.86-3.59 and 2.79; 95% CI, 1.42-5.49 for SASHB 32 to <80% and ≥80% min/h, respectively). A risk score based on age, emergency admission before surgery, and SASHB was associated with the primary outcome (area under receiver operating characteristic curve, 0.73; 95% CI, 0.68-0.77). Similar findings were obtained using a simplified version of SASHB automatically derived from the single oximetry signal extracted from diagnostic sleep studies. CONCLUSIONS AND RELEVANCE: Among OSA patients undergoing major noncardiothoracic surgery, SASHB was significantly associated with the risk of 30-day postoperative mortality and CV complications. Further research is needed to determine whether interventions guided by SASHB scores can modify postoperative risk in patients with OSA.